Nasdaq stocks posting largest percentage increases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
UCB's Brivaracetam Positive in Phase III Epilepsy Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 4:40PM CDT
UCB SA (UCBJF) announced positive top-line results from a phase III study on epilepsy candidate, brivaracetam.
Celgene, Alexion Beat Estimates, But Biotechs Fall
at Investor's Business Daily - Thu Jul 24, 4:07PM CDT
Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector. Celgene's (CELG) Q2 earnings rose 18% over the...
Royal Caribbean and Facebook are big market movers
AP - Thu Jul 24, 3:29PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
Alexion Pharmaceuticals Q2 Earnings In Line; Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:45PM CDT
Alexion (ALXN) reported in line earnings in the second quarter.
Actelion Beats on Q2 Earnings and Sales, Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 1:50PM CDT
Actelion LTD. (ALIOF) reported second-quarter earnings of $2.83 per American Depository Receipt (ADR), up 203.77% from the prior-year earnings of 93 cents per ADR, beating the Zacks Consensus Estimate of $1.37 per share.
Why Biogen Idec Stock Is Firing on All Cylinders
Cory Renauer, The Motley Fool - Motley Fool - Thu Jul 24, 1:00PM CDT
Biogen Idec 's latest earnings report is the envy of the industry as Tecfidera keeps marching toward its multi-billion dollar potential. Beyond multiple sclerosis collaboration revenue from Roche 's best-selling cancer therapy Rituxan continues to...
Illumina (ILMN) Tops Q2 Earnings & Revenues, Ups Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 11:00AM CDT
Illumina (ILMN) reported adjusted earnings of 57 cents per share in the second quarter of 2014, beating the Zacks Consensus Estimate by 6 cents or 11.8%
Video: Celgene, Alexion Earnings Top, But Stocks Fall
at Investor's Business Daily - Thu Jul 24, 10:39AM CDT
Big-cap biotechs Celgene (CELG) and Alexion Pharmaceuticals (ALXN) both modestly beat Q2 estimates and raised their guidance Thursday morning, but their shares were falling in the stock market today as Wall Street seemed to hope for more. Celgene's...
Stock Market News for July 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 9:10AM CDT
Benchmarks finished mostly higher on Wednesday following upbeat quarterly results from healthcare and technology companies
Gilead Crushes Q2 Earnings Estimates as Sovaldi Sales Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:50AM CDT
Gilead (GILD) blew away estimates on strong Sovaldi sales.
The Zacks Analyst Blog Highlights: Biogen Idec, Roche Holding, AbbVie, AmSurg and Acadia Healthcare
PR Newswire - Thu Jul 24, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Biogen Idec Inc. (Nasdaq:BIIB-Free Report), Roche Holding AG (OTC:RHHBY-Free Report), AbbVie Inc. (NYSE:ABBV-Free Report), AmSurg Corp. (Nasdaq:AMSG-Free Report) and Acadia Healthcare Company, Inc. (Nasdaq:ACHC-Free Report).
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
The Medicines Co.'s (MDCO) Q2 Earnings Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:20AM CDT
The Medicines Co. (MDCO) has an important regulatory event coming up with the FDA expected to respond on the approval status of Orbactiv by Aug 6.
Array BioPharma, Inc. (ARRY) Jumps: Stock Surges 10.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:11AM CDT
Array BioPharma, Inc. (ARRY) was a big mover last session, as the company saw its shares rise by nearly 11% on the day.
Biogen Idec (BIIB) Soars: Stock Adds 11.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 7:51AM CDT
Biogen Idec Inc. (BIIB) was a big mover last session, as its shares rose over 11% on the day.
Time to Focus on Biogen Idec (BIIB) for Strong Earnings Growth Potential - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 7:48AM CDT
Biogen Idec possess a favorable Zacks Rank and an impressive long term growth rate
Cramer: Every Which Way But Short
at The Street - Thu Jul 24, 7:03AM CDT
In theory, there should be plenty of shorting opportunities.
Jim Cramer's Top Stock Picks: PEP CELG GILD REGN BIIB CMG
at The Street - Thu Jul 24, 5:00AM CDT
Cramer says Chipotle is a huge winner while his 'four horsemen' of Celgine, Gilead Sciences, Regeneron and Biogen Idec are pulling away from the biotech pack.